ReviewAntibiotics (Basel, Switzerland)2025
Epidemiology and Genetic Traits of Carbapenemase-Producing Enterobacterales: A Global Threat to Human Health.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Prevalence of Carbapenem-Resistant Enterobacteriaceae in Intensive Care Units in Saudi Arabia:Saudi medical journal · 2026Pooled it
- Five years of wastewater surveillance reveal COVID-19-Associated amplification and seasonal shifts inOne health (Amsterdam, Netherlands) · 2026Article
- Prevalence and molecular typing of carbapenem-resistant Enterobacterales in a secondary-care hospital in Jazan region, Saudi Arabia.New microbes and new infections · 2026Article
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Metallo-beta-lactamase α-helix fragment modified peptide N10 is a multifunctional antimicrobial peptide.Microbiology spectrum · 2026Article
- Article
- Genomic characterization ofMicrobiology spectrum · 2026Article
- Phenotypic and genotypic investigation of carbapenemases in carbapenem-resistant Klebsiella pneumoniae isolates.Folia microbiologica · 2026Article
- Insights into antimicrobial resistance: dissemination and molecular epidemiology of carbapenemase and AmpC genes in uropathogenic Escherichia coli.BMC microbiology · 2026Article
- Clinical and Genomic Characterization of High-Risk Multidrug-ResistantMicroorganisms · 2026Article
- Prevalence of carbapenemase production among Enterobacterales with reduced susceptibility to meropenem in patients at Hospital de Clínicas de Porto Alegre (HCPA) between 2019 and 2024.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Phylogenetic Relationships and Structural Conservation ofInternational journal of molecular sciences · 2026Article
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Dissemination of antimicrobial resistance in surface waters: surveillance of enterococci and coliform bacteria in Slovakia.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Genomic analysis of MCR-8 and NDM-5 coproducingBiosafety and health · 2026Article
- Article
- Role of Mobilome in Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Characterization of multidrug-resistant ST363-KL151 Klebsiella variicola clinical isolates harboring blaBMC microbiology · 2026Article
- Diagnostic Performance of Combination Disk and CIM Tests for Carbapenemase Detection in Enterobacterales Compared with Real-Time Multiplex PCR.Infectious diseases & clinical microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Carbapenemase-producing Enterobacterales (CPE) represent an important threat to global health, resulting in an urgent issue in clinical settings. CPE often exhibit a multidrug-resistant (MDR) phenotype, thus reducing the antimicrobial armamentarium, with few antibiotics retaining residual antimicrobial activity against these pathogens. Carbapenemases are divided into three classes (A, B, and D) according to the Ambler classification system. Among these, KPC (class A), NDM, VIM, IMP (class B), and OXA-48-like (class D) represent the most important carbapenemases in terms of diffusion and clinical impact. CPE diffusion has been observed worldwide, with current endemicity in multiple territories around the world. In this context, the clonal spread and plasmid-mediated transmission of carbapenemases have contributed to the global spread of CPE worldwide and to the diffusion of carbapenemases among different Enterobacterales species. In recent years, novel molecules showing excellent in vitro and in vivo activity have been developed against CPE. However, the recent emergence of novel traits of resistance to these molecules has already been reported in several cases, mitigating the initial promising results. This review aims to provide an updated description of the major classes of carbapenemases, their global distribution, and future perspectives to limit the diffusion of CPEs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.